Stifel Financial’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.59M | Buy |
33,017
+14,295
| +76% | +$2.83M | 0.01% | 1178 |
|
|
2025
Q4 | $3.54M | Sell |
18,722
-1,790
| -9% | -$344K | ﹤0.01% | 1538 |
|
|
2025
Q3 | $3.63M | Buy |
20,512
+2,682
| +15% | +$399K | ﹤0.01% | 1481 |
|
|
2025
Q2 | $2.03M | Buy |
17,830
+90
| +0.5% | +$9.62K | ﹤0.01% | 1846 |
|
|
2025
Q1 | $1.87M | Buy |
17,740
+927
| +6% | +$105K | ﹤0.01% | 1810 |
|
|
2024
Q4 | $1.8M | Buy |
16,813
+864
| +5% | +$97.7K | ﹤0.01% | 1854 |
|
|
2024
Q3 | $1.6M | Buy |
15,949
+2,288
| +17% | +$230K | ﹤0.01% | 1923 |
|
|
2024
Q2 | $1.15M | Buy |
13,661
+5,704
| +72% | +$454K | ﹤0.01% | 2081 |
|
|
2024
Q1 | $582K | Buy |
7,957
+771
| +11% | +$56.8K | ﹤0.01% | 2518 |
|
|
2023
Q4 | $513K | Sell |
7,186
-197
| -3% | -$11.6K | ﹤0.01% | 2541 |
|
|
2023
Q3 | $442K | Sell |
7,383
-215
| -3% | -$14.2K | ﹤0.01% | 2561 |
|
|
2023
Q2 | $548K | Buy |
7,598
+3,188
| +72% | +$239K | ﹤0.01% | 2463 |
|
|
2023
Q1 | $324K | Buy |
+4,410
| New | +$313K | ﹤0.01% | 2759 |
|
|
2021
Q1 | – | Sell |
-11,835
| Closed | -$734K | – | 3255 |
|
|
2020
Q4 | $734K | Sell |
11,835
-885
| -7% | -$50.5K | ﹤0.01% | 2070 |
|
|
2020
Q3 | $755K | Buy |
12,720
+1,082
| +9% | +$73.8K | ﹤0.01% | 1825 |
|
|
2020
Q2 | $812K | Buy |
11,638
+4,636
| +66% | +$294K | ﹤0.01% | 1710 |
|
|
2020
Q1 | $318K | Sell |
7,002
-111,604
| -94% | -$6.33M | ﹤0.01% | 2143 |
|
|
2019
Q4 | $7.73M | Sell |
118,606
-8,247
| -7% | -$551K | 0.02% | 704 |
|
|
2019
Q3 | $7.81M | Sell |
126,853
-48,956
| -28% | -$3.07M | 0.02% | 651 |
|
|
2019
Q2 | $12.6M | Buy |
175,809
+14,138
| +9% | +$1.04M | 0.03% | 485 |
|
|
2019
Q1 | $12.7M | Sell |
161,671
-1,027
| -0.6% | -$77.8K | 0.04% | 452 |
|
|
2018
Q4 | $13.8M | Buy |
162,698
+27,020
| +20% | +$2.88M | 0.04% | 379 |
|
|
2018
Q3 | $23.2M | Sell |
135,678
-56,895
| -30% | -$8.58M | 0.07% | 277 |
|
|
2018
Q2 | $24.9M | Buy |
192,573
+2,821
| +1% | +$315K | 0.08% | 258 |
|
|
2018
Q1 | $19.5M | Buy |
189,752
+9,588
| +5% | +$948K | 0.06% | 312 |
|
|
2017
Q4 | $15.4M | Buy |
180,164
+5,238
| +3% | +$454K | 0.05% | 375 |
|
|
2017
Q3 | $14.8M | Buy |
174,926
+163,620
| +1,447% | +$13M | 0.05% | 368 |
|
|
2017
Q2 | $857K | Buy |
11,306
+162
| +1% | +$11.3K | ﹤0.01% | 1549 |
|
|
2017
Q1 | $736K | Buy |
11,144
+670
| +6% | +$44.1K | ﹤0.01% | 1613 |
|
|
2016
Q4 | $666K | Buy |
10,474
+3,703
| +55% | +$234K | ﹤0.01% | 1616 |
|
|
2016
Q3 | $427K | Buy |
6,771
+3,310
| +96% | +$243K | ﹤0.01% | 1803 |
|
|
2016
Q2 | $259K | Buy |
+3,461
| New | +$257K | ﹤0.01% | 2125 |
|
|
2016
Q1 | – | Sell |
-5,316
| Closed | -$360K | – | 2322 |
|
|
2015
Q4 | $360K | Buy |
+5,316
| New | +$328K | ﹤0.01% | 1821 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Stifel Financial's LGND Position: Q1 2026 in Review
Stifel Financial increased its Ligand Pharmaceuticals (LGND) stake by 76% in Q1 2026, buying an estimated $2.83M and bringing the position to 33,017 shares worth $6.59M. The position accounts for 0.01% of the portfolio, ranked #1178.
Stifel Financial first reported a position in LGND in Q4 2015 and has held it in 33 quarters since. The position peaked at $24.9M in Q2 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Stifel Financial held 33,017 shares of Ligand Pharmaceuticals worth $6.59M as of Q1 2026.
- Stifel Financial bought 14,295 Ligand Pharmaceuticals shares in Q1 2026, an estimated $2.83M.
- Ligand Pharmaceuticals made up 0.01% of Stifel Financial's portfolio in Q1 2026, its #1178 holding.
- Stifel Financial first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 33 quarters since.
- Stifel Financial's Ligand Pharmaceuticals position peaked at $24.9M in Q2 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.